Hereditary breast cancer: Clinical features and risk reduction strategies

Annals of Oncology

Volumn 22, Issue SUPPL. 1, 2011, Pages

  Paradiso, A ^a   Formenti, S ^b  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOTOXIC AGENT; EXEMESTANE; PLACEBO; RALOXIFENE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DRUG EFFICACY; FAMILIAL CANCER; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MASTECTOMY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 79551643321     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq663     Document Type: Article

References (39)

1. Newman B, Mu H, Butler LM. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279: 915-921.
2. Ford D, Easton DF, Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
4. Antoniou A, Pharoah P, Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
5. Chen S, Iversen ES, Friebel T. et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006; 24: 863-871.
6. Warner E, Plewes DB, Hill KA. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-1325.
7. Metcalfe K, Lynch HT, Ghadirian P. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22: 2328-2335.
8. Kauff ND, Domchek SM, Friebel TM. et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331-1337.
9. Litton JK, Westin SN, Ready K. et al. Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation Cancer 2009; 115: 1598-1604.
10. Zhong Q, Chen CF, Li S. et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999; 285: 747-750.
11. Formenti SC, Preston-Martin S. BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity? J Clin Oncol 2000; 18: 1159-1160.
12. Xia F, Powell S. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol 2002; 12: 296-304.
13. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007; 43: 238-257.
14. Robson M, Levin D, Federici J. et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999; 91: 2112-2117.
15. Haffty BG, Harrold E, Knan AJ. et al. Outcome of conservatively managed earlyonset breast cancer by BRCA1/2 status. Lancet 2002; 359: 1471-1477.
16. Robson M, Chappuis PO, Satapogan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8-R17.
17. Pierce LJ, Levin AM, Rebbeck TR. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-2443.
18. Garcia-Etienne CA, Barile M, Gentilini OD. et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009; 16: 3380-3387.
19. Pierce LJ, Phillips KA, Griffith KA. et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010; 121: 389-398.
20. Fourquet A, Stoppa-Lyonnet D, Kirova YM. et al. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 2009; 32: 127-131.
21. Byrski T, Gronwald J, Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
23. Gronwald J, Tung N, Foulkes WD, Offit K. et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118: 2281-2284.
24. Visvanathan K, Chlebowski RT, Hurley P. et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27: 3235-3258.
25. King MC, Wieand S, Hale K. et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 2001; 286: 2251-2256.
26. Van Sprundel TC, Schmidt MK, Rookus MA. et al. Risk reduction and survival after contralateral prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2005; 93: 287-292.
27. Metcalfe KA, Lubinski J, Ghadirian P. et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26: 1093-1097.
28. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008; 122: 2017-2022.
29. Struewing JP, Hartge P, Wacholer S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
30. Satagopan JM, Boyd J, Kauff ND. et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8: 3777-3781.
31. Antoniou A, Pharoah PD, Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 mutation detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1139.
32. Rebbeck TR, Lynch HT, Neuhausen SL. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
33. Kauff ND, Satagopan JM, Robson ME. et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
34. Finch A, Beiner M, Lubinski J. et al. Salpingo-oophorectomy and the risk of ovarian, Fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296: 185-192.
35. Kramer J, Velazquez I, Chen BS. et al. Prophylactic ooporectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005; 23: 8629-8635.
36. Kauff N, Domcheck S, Friebel T. et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multi-center, prospective study. J Clin Oncol 2008; 26: 1331-1337.
37. Rebbeck TR, Kraff ND, Domcheck SM. Meta-analysis of risk-reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA 2 mutation carriers. J Natl Cancer Inst 2008; 101: 80-87.
38. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000; 283: 617-624.
39. Anderson K, Jacobson JS, Heitjan DF. et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006; 144: 397-406.